Alfacell Provides Update on the ONCONASE Phase IIIb Registration Trial Alfacell Corporation today provided an update on the status of the ongoing confirmatory Phase IIIb registration trial evaluating ONCONASE , the Company's lead investigational drug candidate, as a treatment for
unresectable malignant mesothelioma :

Asbestos Treatment NHS Row
A DRUG that can help fight an asbestos-related cancer has been rejected for NHS use due to cost. Mesothelioma sufferers in England and Wales will not be prescribed the treatment that can extend lives by months. But it is available to sufferers in Scotland.

HOME PAGE
Timeline to deal The Mittal-Arcelor saga started earlier this year. Here's how the story unfolded.... January 27: Mr L.N. Mittal made an unsolicited $22.7-billion bid for Arcelor. But Arcelor rejected that bid on the pretext that the two companies did ...

Pesticides Exposure Associated With Parkinson's Disease A large-scale, prospective study has shown links between chronic, low-doseexposure to pesticides and Parkinson's disease.

Professor from Loyola joins isle cancer center Dr. Michele Carbone, lead investigator for two National Cancer Institute grants totaling $3.5 million, has joined the Cancer Research Center of
Hawaii.